I'm with you Drano. Here's a quick discussion I had this

New Post Public Reply Private Reply Replies (2) Message Board
BooDog Drano #15685
I'm with you Drano. Here's a quick discussion I had this morning. Many mentioned here but mainly CTIX and AVXL. Also still seeing sunsplat on the ctix board, relentless misrepresentation trying to implant BS.

Quote:
The manipulation is unreal. 123tom mentioned a few and a group I hang with that primarily shorts stocks (I'll explain more in a bit) reminded me of a couple others, UQM and MDBX. Stocks that get a MAJOR spike and then crash right back down. We've seen some others just this year. I don't short, but it can be done the right way without torturing or being malicious ~ the way it was meant to be. My other group is BP Rising, they simply peg the resistance and cover on the support. Not being greedy like some of the hedge funds or groups like Adam F. Helps me too sometimes, when they start covering and support is confirmed, I can go long again with a bit more confidence. Most of their plays are out of my price range or I hardly seem to have the funds available at the right time.

AVXL wasn't much different as far as the spike went, a lot of hype driving it so many knew the peak wouldn't be sustainable. I like and I use the same strategy gfp927z (what is that ID short for?)...

Quote:

But there is a way to own bio stocks for the longer haul, instead of merely trading them. You can have small positions in a group of favorites and just let them ride for as long as their fundamentals continue to look good. That's how successful private equity outfits like the Baker Bros do it. Another approach is to have a core position and a trading position. For myself I'm content to just follow them out of general interest and for the entertainment value. If I decide to actually invest money again, the strict limit will be $1000 per stock. With this approach you won't get rich, but you'll stay out of trouble.




I have been consistently using both. Light positions in a stock and then loading back up when the chart says to or well ahead of a catalyst and then taking some off around the event or pulling a stop loss if need be. MSTX has been in a sideways range for some time but also has a couple nice catalysts, one soon (by mid December?) and then more on their EPIC study 1q 2016. Took some back off around .43 since the technical weakened but looking to add back on it. ATNM CBAY SYN CTIX CRBP I've been doing the same thing. Took some profits from AVXL and loaded CBAY just in time for it to pull back on me, reminding me not to be so quick to follow the intraday when I'm looking for a longer term swing.
Speaking of intradays, AVXL, 2 days in a row screwed me over, the only thing that saved me from adding back in was the lack of confirmation. Crowin had it right both times on the AVXL thread, I don't follow him and think he may be more of a short but I do try and keep an open mind and not just ignore other ideas. I'm just another rock in the pond so if I see something that might give me an edge I'll take heed and at least be a bit more cautious. I was looking for the 200 dma to hold up better but the low float adds to this volatility. The intraday was showing signs of forming a falling wedge reversal from the daily. My idea was to combine the daily and throw in the intraday, I also mentioned in my post that we'd need to see confirmation. My wedge fell apart shortly after I posted. Is it just shorts? It could be, I didn't see any insider selling. Though I am missing a little over 300K shares post split from the form 5 annual statement and my calculations of the form 4's pre split. Too many posts to go through to see if anyone else addressed that or even caught it. When buyers are staying away or longs are just sitting tight, whatever action there is causing so much volatility but the overall trend is manipulated down because (IMO) hedge funds are whacking out the bid. I think there is institutional interest and whoever it is doing what they can to get whatever they can as low as they can. We'll find out in Jan early Feb when the new numbers come out. Like CTIX, we should see the interest continue so money will be watching. Just need to see if Anavex has something up their sleeve to spark things in the right direction. I'm putting AVXL on early pincher radar soon but it needs to set up a bit more. Divergence still looks a bit weak. Starting to head into the oversolds.
I do like your strategy Gfp927z, have some AVXL in the $4's and looking to load up.
News on ATNM as well so may be able to play that into adding on AVXL. BTW, AVXL on S Ttwits now has over 2013 followers.




Quote:

gfp927z Wednesday, 11/18/15 09:58:04 AM
Re: BooDog post# 1048
Post # of 1049


BooDog, With AVXL they're using the usual shorting techniques like forcing down the bid, but other than the brief Feuerstein article there wasn't a huge accompanying hit piece of the type that happened with CTIX, where they not only trash in great detail the science, but also the CEO and other management's dubious history. The CTIX hit job took months to plan and was a major production, in contrast to AVXL which looks like a one time 'short and move on' opportunity for the short crowd.

AVXL just got way ahead of itself on the upside, having a $500 mil market cap based on a tiny open label Phase 2a. The CEO Missling is a straight arrow compared to Erlich of CTIX, so there wasn't the required ammo for a full fledged long term assault on the stock, in contrast to CTIX. So I'm figuring the AVXL shorts will cover and move on to their next prey and leave the stock alone to gradually recover.

The clinical evidence of efficacy is very early, but AVXL is a potential lotto stock due to the extreme lack of effective Alzheimer's treatments - there are none. The ACHase inhibitors like Aricept, and the NMDA inhibitor Namenda, are basically worthless, but have racked up many billions in sales only because there is no other treatment available. As long as that's the case, interest in AVXL will return. According to Dr. Tracy of NeuroPerspective, AVXL's approach (Sigma-1 receptor) is getting renewed interest in the pharma world. So AVXL has potential as a high risk longer term lotto stock, with a solid CEO in Missling and a $50 mil financing arrangement in place.


Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Supply Maverick Simplifies Global Shipping Processes

Updated Category News Views 5

Paving the Way for Seamless International Shipping Supply Maverick's got a new mantra, folks: simplicity. They're slicing through the mess of international shipping and bringing some much-needed clarity for customers in Canada, Australia, and New Zealand. It’s about time someone shook up the logistics playbook. The Nuts and Bolts of the New Shipping System Imagine being...

Continue Reading
Fermi's Founder Pushes for Board Overhaul: What's Next?

Updated Category News Views 4

Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...

Continue Reading
Melissa Rivers Brings Her Wit Back to Emmys Carpet

Updated Category News Views 12

They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...

Continue Reading
High-Grade Copper Spurs Optimism for PolarX in Alaska

Updated Category News Views 4

Copper's New Pulse: PolarX Makes Waves in Alaska Ever hear about striking copper so rich it's practically shimmering? Well, PolarX Limited just might have hit that sweet spot up in the rugged expanses of Alaska. Let me tell you, when you're knee-deep in resources, like what they’re discovering at the Caribou Dome Project, it sure feels like you’ve struck modern-day...

Continue Reading
Americas Cardroom's Poker Series Hits $7.2M Haul

Updated Category News Views 6

Massive Prize Pools Emerge in Just Four Days I found myself eyeballing some jaw-dropping numbers from Americas Cardroom's latest poker series, the Online Super Series XL. It's not every day you see nearly a hundred tournaments rake in over $7.2 million in prize pools in just four days. From September 6th to 9th, a whopping 62,847 entries signed up to make an honest...

Continue Reading
QuickFi Nabs Top Finovate Award for Fourth Time

Updated Category News Views 5

An Unstoppable Force in Fintech Well, if QuickFi hasn't made a name for itself in fintech, then folks, I don't know what to tell you. This year, they’ve snagged yet another prestigious Finovate Award—this time for Best SMB/SME Banking Solution. That's not their first rodeo either; it’s the fourth time they’ve walked away winners. It's almost like they're...

Continue Reading
Modeling and Mental Health Join Forces for Wellness

Updated Category News Views 5

A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...

Continue Reading
DCM Services Teams with AKUVO to Boost Estate Recoveries

Updated Category News Views 14

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

Continue Reading
Jari Spirits Set to Shake Up U.S. Market After Big Wins

Updated Category News Views 4

Korean Spirits Jari Eyes U.S. Market Entry Some stories just have that perfect 'right time, right place' vibe, and CJ Foods' recent splash with their Korean spirits brand jari is one of them. Buckle up, because this one's about a Korean distilling sensation gearing up to hit American shores with a bang. Accolades Pave the Path Jari, the premium Korean distilled spirits...

Continue Reading
Intus Bio Secures $2.7M for Colorectal Cancer Test

Updated Category News Views 6

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

Continue Reading

Top 5 Most Recently Viewed Articles

Atos Annual General Meeting Highlights and Board Changes

Updated Category News Views 133

Key Highlights from Atos Annual General Meeting Atos, a global digital transformation leader, has officially convened its Annual General Meeting (AGM) focused on enhancing corporate governance and approving pivotal financial statements. This meeting aims to highlight vital changes within the Board of Directors while ensuring stakeholders are informed and engaged. Overview...

Continue Reading
NRSInsights Reports Robust Growth in Retail Sales for October

Updated Category News Views 59

October Retail Sales Growth Highlights October same-store sales saw a noteworthy increase of 3.7% year-over-year, indicating a strong consumer demand. In a recent report from NRSInsights, a prominent analytics provider leveraging data from the National Retail Solutions (NRS) point-of-sale system, retail sales for October 2024 have shown promising trends. Approximately...

Continue Reading
Understanding Alliance Witan PLC's Net Asset Valuation Insights

Updated Category News Views 112

Understanding Alliance Witan PLC's Financial Standing Alliance Witan PLC stands out in the investment landscape, offering its shareholders a detailed look at their Net Asset Value (NAV). As of the latest reporting date, the financial metrics reveal significant information pertaining to the company's performance and shareholder value. Net Asset Value Calculation At the...

Continue Reading
Discover the Remarkable Returns of Vulcan Materials Stock

Updated Category News Views 141

Unveiling Vulcan Materials Company Stock Performance Vulcan Materials Co. (NYSE: VMC) has been a noteworthy performer in the stock market over the past 15 years, surpassing market expectations with a commendable annual return of 15.1%. This stock has consistently outperformed the market, achieving an admirable 2.86% advantage annually. With a current market capitalization...

Continue Reading
Vroom Unveils Comprehensive Long-term Vision for Growth

Updated Category News Views 63

Vroom Reveals New Strategic Plan for Future Success Vroom, Inc. (Nasdaq: VRM) has unveiled its long-term strategic plan, offering a clear roadmap that outlines the company's aspirations and critical initiatives for the future. This announcement was made through an investor presentation, which elaborated on how Vroom plans to improve its operational efficiency and overall...

Continue Reading